
{
    "credit": [
        {
            "email": "drmafei@126.com",
            "name": "Fei Ma",
            "typeEntity": "Person",
            "typeRoles": [
            ]
        },
        {
            "email": "xubinghe@medmail.com.cn",
            "name": "Binghe Xu",
            "typeEntity": "Person",
            "typeRoles": [
            ]
        }
    ],
    "function": [
        {
            "operation": [
                {
                    "term": "Pathway or network prediction",
                    "uri": "http://edamontology.org/operation_3439"
                },
                {
                    "term": "Genotyping",
                    "uri": "http://edamontology.org/operation_3196"
                },
                {
                    "term": "PCR primer design",
                    "uri": "http://edamontology.org/operation_0308"
                }
            ]
        }
    ],
    "labels": {
        "topic": [
            {
                "term": "DNA polymorphism",
                "uri": "http://edamontology.org/topic_2885"
            },
            {
                "term": "Pharmacogenomics",
                "uri": "http://edamontology.org/topic_0208"
            },
            {
                "term": "Oncology",
                "uri": "http://edamontology.org/topic_2640"
            },
            {
                "term": "Molecular interactions, pathways and networks",
                "uri": "http://edamontology.org/topic_0602"
            },
            {
                "term": "Endocrinology and metabolism",
                "uri": "http://edamontology.org/topic_3407"
            }
        ]
    },
    "publication": [
        {
            "doi": "10.1186/S40880-019-0399-Z",
            "pmcid": "PMC6787984",
            "pmid": "31601265"
        }
    ],
    "summary": {
        "biotoolsCURIE": "biotools:TYMS_rs2853741_MTHFR_rs3737964_MTHFR",
        "biotoolsID": "TYMS_rs2853741_MTHFR_rs3737964_MTHFR",
        "description": "Polymorphisms of MTHFR and TYMS predict capecitabine-induced hand-foot syndrome in patients with metastatic breast cancer.\n\nBACKGROUND:Breast cancer is a global problem, and a large number of new cases are diagnosed every year. Capecitabine is effective in patients with metastatic breast cancer (MBC). Hand-foot syndrome (HFS) is a common adverse effect of capecitabine. In this study, we investigated the association between single nucleotide polymorphisms (SNPs) in genes involved in capecitabine metabolism pathways and capecitabine-induced HFS in Chinese patients with MBC to identify some predictive genetic biomarkers. METHODS:We selected 3 genes involved in capecitabine metabolism and screened genetic variants in these target genes.\n\n||| HOMEPAGE MISSING!.\n\n||| CORRECT NAME OF TOOL COULD ALSO BE 'rs2853741 MTHFR rs3737964 MTHFR rs4846048', 'TYMS rs2606241 TYMS rs2853741 MTHFR', 'rs2606241 TYMS rs2853741 MTHFR rs3737964', 'MTHFR rs3737964 MTHFR rs4846048'",
        "homepage": "https://www.ncbi.nlm.nih.gov/pubmed/?term=31601265",
        "name": "TYMS rs2853741 MTHFR rs3737964 MTHFR"
    }
}